低位直肠癌新辅助放化疗后治疗新策略

doi:10.3760/cma.j.issn.1673-422X.2018.10.012

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (10): 632-634.doi: 10.3760/cma.j.issn.1673-422X.2018.10.012

低位直肠癌新辅助放化疗后治疗新策略

柳麒,孙伟子,魏艳,彭晋,周福祥

430071 武汉大学中南医院放化疗科湖北省肿瘤医学临床研究中心肿瘤生物学行为湖北省重点实验室

收稿日期:2018-06-13 出版日期:2018-10-08 发布日期:2018-12-21
通讯作者: 周福祥 E-mail:happyzhoufx@sina.com
基金资助:
武汉大学中南医院科技创新培育基金（cxpy20160042）

New treatment strategy after neoadjuvant chemoradiotherapy in low rectal cancer

Liu Qi, Sun Weizi, Wei Yan, Peng Jin, Zhou Fuxiang

Department of Radiation Oncology and Medical Oncology, Zhongnan Hospital of Wuhan University; Hubei Cancer Clinical Study Center; Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan 430071, China

Received:2018-06-13 Online:2018-10-08 Published:2018-12-21
Contact: Zhou Fuxiang E-mail:happyzhoufx@sina.com
Supported by:
hongnan Hospital of Wuhan University of Science and Technology Innovation Cultivation Foundation （cxpy20160042）

摘要/Abstract

摘要： 直肠癌是我国最常见的恶性肿瘤之一，其中以低位直肠癌发病率最高。随着对直肠癌生物学行为的深入研究和诊断治疗技术的发展，肿瘤学家对低位直肠癌提出了新的治疗策略——局部切除、等待观察策略。该策略在不失传统标准治疗模式较好的肿瘤控制的情况下，能够更好地保全肛门功能，患者有更好的生命质量。

关键词: 直肠肿瘤, 肿瘤辅助疗法, 局部切除, 等待观察

Abstract: Rectal cancer is one of the most common malignant tumor in our country, among them with highest incidence of low rectal cancer. With the further study on the biological behavior of rectal cancer and the development of diagnostic and therapeutic techniques, gastrointestinal oncologists have proposed a new treatment strategy local resection and wait-and-see. This strategy can better preserve anal function and improve the quality of life of patients without losing the good tumor control of the traditional standard treatment model.

Key words: Rectal neoplasms, Neoadjuvant therapy, Local excision, Wait-and-see

柳麒,孙伟子,魏艳,彭晋,周福祥. 低位直肠癌新辅助放化疗后治疗新策略[J]. 国际肿瘤学杂志, 2018, 45(10): 632-634.

Liu Qi, Sun Weizi, Wei Yan, Peng Jin, Zhou Fuxiang. New treatment strategy after neoadjuvant chemoradiotherapy in low rectal cancer[J]. Journal of International Oncology, 2018, 45(10): 632-634.

参考文献

［1］ Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338. ［2］卫洪波, 郑宗珩. 超低位直肠癌保肛手术技术及革新［J］. 国际外科学杂志, 2016, 43(1): 8-10. DOI: 10.3760/cma.j.issn.1673-4203.2016.01.003. ［3］中华人民共和国卫生和计划生育委员会医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017年版)［J］. 中华外科杂志, 2018, 56(4): 241-258. DOI: 10.3760/cma.j.issn.05295815.2018.04.001. ［4］ Paun BC, Cassie S, MacLean AR, et al. Postoperative complications following surgery for rectal cancer［J］. Ann Surg, 2010, 251(5): 807-818. DOI: 10.1097/SLA.0b013e3181dae4ed. ［5］ Marijnen CA. Organ preservation in rectal cancer: have all questions been answered?［J］. Lancet Oncol, 2015, 16(1): e13-e22. DOI: 10.1016/S1470-2045(14)70398-5. ［6］ Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median followup of 11 years［J］. J Clin Oncol, 2012, 30(16): 1926-1933. DOI: 10.1200/JCO.2011.40.1836. ［7］ Lezoche E, Baldarelli M, Lezoche G, et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy［J］. Br J Surg, 2012, 99(9): 1211-1218. DOI: 10.1002/bjs.8821. ［8］ GarciaAguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an openlabel, singlearm, multiinstitutional, phase 2 trial［J］. Lancet Oncol, 2015, 16(15): 1537-1546. DOI: 10.1016/S1470-2045(15)00215-6. ［9］德吉, 秦金玉, 王瑾, 等. 早期结直肠癌淋巴结转移的危险因素分析及内镜切除指征的探讨［J］. 中华消化内镜杂志, 2015, 32(6): 367-370. DOI: 10.3760/cma.j.issn.1007-5232.2015.06.003. ［10］ Yeo SG, Kim DY, Kim TH, et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: longterm outcomes and prognostic significance of pathologic nodal status (KROG 0901)［J］. Ann Surg, 2010, 252(6): 998-1004. DOI: 10.1097/SLA.0b013e3181-f3f1b1. ［11］ Smith JJ, Chow OS, Gollub MJ, et al. Organ preservation in rectal adenocarcinoma: a phase Ⅱ randomized controlled trial evaluating 3year diseasefree survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management［J］. BMC Cancer, 2015, 15: 767. DOI: 10.1186/s12885-015-1632-z. ［12］ Maas M, Nelemans PJ, Valentini V, et al. Longterm outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data［J］. Lancet Oncol, 2010, 11(9): 835844. DOI: 10.1016/S14702045(10)701728. ［13］ HabrGama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: longterm results［J］. Ann Surg, 2004, 240(4): 711-717, discussion 717-718. ［14］ Maas M, BeetsTan RG, Lambregts DM, et al. Waitandsee policy for clinical complete responders after chemoradiation for rectal cancer［J］. J Clin Oncol, 2011, 29(35): 4633-4640. DOI: 10.1200/JCO.2011.37.7176. ［15］ Renehan AG, Malcomson L, Emsley R, et al. Watchandwait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensityscore matched cohort analysis［J］. Lancet Oncol, 2016, 17(2): 174-183. DOI: 10.1016/S14702045(15)00467-2. ［16］杨庆, 张涛. 直肠癌新辅助治疗后临床完全缓解的评估［J］. 现代肿瘤医学, 2016, 24(17): 2815-2819. DOI: 10.3969/j.issn.1672-4992.2016.17.043. ［17］ Ryan JE, Warrier SK, Lynch AC, et al. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review［J］. Colorectal Dis, 2015, 17(10): 849-861. DOI: 10.1111/codi.13081. ［18］ Rullier E, Rouanet P, Tuech JJ, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, openlabel, multicentre, phase 3 trial［J］. Lancet, 2017, 390(10093): 469-479. DOI: 10.1016/S0140-6736(17)31056-5.

[1]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[6]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[7]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[8]	徐放, 朱文钿. 肝细胞癌合并微血管侵犯术后辅助治疗现状[J]. 国际肿瘤学杂志, 2023, 50(5): 304-309.
[9]	曾利武, 杜雨强, 张鹏, 陶凯雄. 直肠癌侧方淋巴结转移的影像评估进展[J]. 国际肿瘤学杂志, 2023, 50(4): 248-251.
[10]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺. 结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[11]	徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[12]	刘玉杰, 赵志强, 王子琤. 早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[13]	巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.
[14]	陶红, 殷红, 罗宏, 陶佳瑜. 靶向肿瘤相关巨噬细胞增强结直肠癌免疫检查点抑制剂疗效的潜在策略[J]. 国际肿瘤学杂志, 2023, 50(11): 683-687.
[15]	王熙, 吴川清. 结直肠癌多药耐药逆转的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 42-46.

低位直肠癌新辅助放化疗后治疗新策略

New treatment strategy after neoadjuvant chemoradiotherapy in low rectal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价